Tag: Cancer: Lung
2000 to 2011 Saw Shift in Treatment for Advanced NSCLC
Rise in use of pemetrexed, erlotinib, bevacizumab; longest treatment duration with these agents
Atezolizumab Effective in Late-Stage Non-Small-Cell Lung Cancer
Drug can extend survival by several months, with fewer adverse events
Stepped Care Likely to Be Cost-Effective in Head & Neck, Lung CA
Mean costs lower and mean number of quality-adjusted life-years higher in intervention group
Osimertinib Bests Platinum-Pemetrexed in T790M+ NSCLC
Significantly longer duration of progression-free survival with osimertinib vs platinum-pemetrexed
Intermittent Hypoxia Promotes Lung Tumor Cell Aggressiveness
IH-induced exosomes from mice significantly promote TC1 malignant properties
Updated Index Predicts Survival in NSCLC With Brain Metastases
Significant prognostic factors include four factors from earlier index, plus EGFR and ALK alterations
Pembrolizumab Ups Survival in NSCLC With PD-L1 Expression
Findings in patients with advanced NSCLC with PD-L1 expression on at least 50 percent of tumor cells
Changes in Depression Symptoms Tied to Mortality in Lung Cancer
Increased risk with new-onset depression, persistent depression, but not depression symptom remission
Lung Cancer Decision Aids Are Helpful for Patients
Patient understanding of lung cancer screening increased after participation in focus groups
ASTRO: SBRT Ups Survival in Older Early-Stage NSCLC Patients
Findings suggest SBRT should be standard for patients treated with radiation for stage I NSCLC
